Edition:
United Kingdom

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

38.19USD
19 Jan 2018
Change (% chg)

$0.80 (+2.14%)
Prev Close
$37.39
Open
$37.64
Day's High
$38.28
Day's Low
$37.64
Volume
111,785
Avg. Vol
257,463
52-wk High
$38.74
52-wk Low
$13.51

Select another date:

Mon, Jan 8 2018

BRIEF-Adamas Announces U.S. Commercial Launch Of Gocovri, The First FDA-Approved Medication For Treatment Of Dyskinesia In Parkinson's Disease Patients

* ADAMAS ANNOUNCES U.S. COMMERCIAL LAUNCH OF GOCOVRI™ THE FIRST AND ONLY FDA-APPROVED MEDICATION FOR THE TREATMENT OF DYSKINESIA IN PARKINSON’S DISEASE PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals reports Q3 loss per share $1.04

* Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results

BRIEF-Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals

* Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing‍​ Source text (http://bit.ly/2zY2CVE) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma‍​

* Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing‍​ Source text : (http://bit.ly/2lnW6oI) Further company coverage:

BRIEF-Adamas Pharmaceuticals says FDA recognizes orphan drug exclusivity for GOCOVRI

* FDA recognizes orphan drug exclusivity for Adamas’ GOCOVRI Source text for Eikon: Further company coverage:

BRIEF-Adamas appoints Mardi C. Dier to its board of directors

* Adamas appoints Mardi C. Dier to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Adamas Pharmaceuticals says unit entered into amended and restated API supply agreement with Moehs Ibérica

* Adamas Pharmaceuticals says ‍on Oct 4, unit entered into amended and restated API supply agreement with Moehs Ibérica - SEC Filing

BRIEF-Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals‍​

* Millennium Management LLC reports a 5.6 pct passive stake in Adamas Pharmaceuticals as of August 29 - SEC filing ‍​ Source text: [http://bit.ly/2xSxczx] Further company coverage:

BRIEF-Adamas announces topline phase 1b data of ADS-4101 for the treatment of partial onset seizures in epilepsy

* Adamas announces topline phase 1b data of ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy

Adamas Pharma secures approval for Parkinson's dyskinesia drug

The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc's treatment for a side effect caused by a commonly prescribed Parkinson's drug, sending the shares of the drugmaker soaring in after-market trading.

Select another date: